In what is believed to be the largest genetic analysis of what triggers and propels progression of tumor growth in a common childhood blood cancer, researchers at 嘿嘿视频 Medical Center report that they have identified a possible new drug target for treating the disease.
T-cell acute lymphoblastic leukemia is one of the most common and aggressive childhood blood cancers. An estimated quarter of the 500 adolescents and young adults diagnosed with the cancer each year in the U.S. fail to achieve remission with standard chemotherapy drugs.
In a cover-story report set to appear in the journal Cell online July 31, the 嘿嘿视频 team describes how they used advanced genetic scanning techniques to identify 6,023 so-called long, non-coding strands of RNA, vital chemical cousins of DNA, that were active in the immune system T cells taken from 15 boys and girls with T-cell acute lymphoblastic leukemia, but not active in the healthy T cells in three young people without the disease.
Study investigators say LUNAR1 was not singled out from RNA typically used by DNA to make proteins, but rather from among the most prevalent RNA 鈥 long chemical strands of translated DNA, previously termed 鈥渏unk DNA鈥 鈥 which can help transcribe DNA but never fully assemble proteins. They say these long non-coding RNAs are increasingly recognized as key to regulating many cell functions.
Senior study investigator and 嘿嘿视频 cancer biologist , says the study offers preliminary evidence that drugs blocking LUNAR1 could treat T-cell acute lymphoblastic leukemia and could be a long-sought alternative to chemotherapeutic drugs that kill both cancer and normal cells.
Aifantis, a professor and chair of pathology at the Laura and Isaac Perlmutter Cancer Center at 嘿嘿视频, and an early career scientist at the Howard Hughes Medical Institute, also says LUNAR1 could aid in diagnosing the blood cancer.
鈥淥ur study shows that LUNAR1 is highly specific for T-cell acute lymphoblastic leukemia and plays a key role in how this cancer develops,鈥 he says, pointing out that overproduction of LUNAR1 was recorded in almost all (90 percent) of leukemia patients tested.
Moreover, Aifantis says, his team鈥檚 latest findings suggest that development of future cancer therapies based on the underlying genetics of each patient should involve 鈥渘ot just mutations in someone鈥檚 DNA, but also alterations in the makeup of RNA.鈥
Among the study鈥檚 other key findings was that while LUNAR1 does not produce cancerous proteins on its own, its production was essential to the cell-to-cell signaling action of another protein, insulin-like growth factor 1 receptor (IGF-1R), already tied to many cancers, including leukemia.
Further laboratory experiments showed that the gene coding for LUNAR1 is near the gene for IGF-1R and located toward the chromosomes鈥 ends, known as telomeres. When activated, LUNAR1鈥檚 position allows it to chemically loop back and, in turn, bind to and activate IGF-1R.
Researchers zeroed in on LUNAR1 by pinpointing those RNAs that also were active in the NOTCH1 biological pathway. They say the NOTCH1 pathway is common to many cancers, but is especially active in at least half of all people with T-cell acute lymphoblastic leukemia. LUNAR1 stood out right away, they say, as the most highly expressed long, non-coding RNA, of which more than half were newly discovered.
According to Aifantis, his team鈥檚 research shows that T-cell acute lymphoblastic leukemia, as is the case in many other cancers, could be simply described as a condition of 鈥渢oo much errant signaling.鈥 He says in normal T cells, the long, non-coding RNAs such as LUNAR1 are not transcribed, NOTCH1 is inactive, and there is no looping back of LUNAR1 to activate IGF-1R.
To confirm their findings, researchers also transplanted human leukemia T cells into mice to prompt tumor growth, and chemically blocked LUNAR1 in some of the animals. Tumor growth stalled only in those mice whose LUNAR1 was inactivated.
Aifantis says his team鈥檚 next steps are to develop more effective inhibitors of LUNAR1, preferably something that would precisely target any one or more of its 200-plus component nucleotides.
Funding support for the study was provided by the U.S. National Cancer Institute and National Institute of General Medical Sciences, both parts of the National Institutes of Health. Corresponding federal grant numbers are P30 CA016087-30, R01 CA133379, R01 CA149655, R01 CA173636, R01 169784, R01 GM088847, and T32-CA009161-37. Further funding support was provided by the William Lawrence and Blanche Hughes Foundation; the Leukemia and Lymphoma Society (corresponding grant numbers TRP#6340 -11 and LLS#6373-13), the Chemotherapy Foundation, the Irma T. Hirschl Trust, the V Foundation for Cancer Research, and the St. Baldrick鈥檚 Foundation.
Besides Aifantis, other 嘿嘿视频 researchers involved in these experiments were lead study investigator Thomas Trimarchi, BSc, and study co-investigators Panagiotis Ntziachristos, PhD, and Aristotelis Tsirigos, PhD. Additional research support was provided by Erhan Bilal, PhD, at the IBM Thomas J. Watson Research Center; and Giulia Fabbri, PhD, and Riccardo Dalla-Favera, MD, at Columbia University in New York.
Media Inquiries
David March
Phone: 212-404-3528
david.march@nyumc.org
